Month: September 2021

–If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids– -NDA submission includes positive data from Phase 3 PRIMROSE trials up to 52 weeks on treatment and 24 weeks post-treatment follow-up results- -EU MAA CHMP recommendation anticipated in Q4 2021-   Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland– September 15, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for linzagolix for the treatment of uterine fibroids. Linzagolix is an oral GnRH receptor antagonist...

Marseille, Sept. 15, 2021 (GLOBE NEWSWIRE) —First data set from lacutamab TELLOMAK trial demonstrated encouraging 35% overall global response rate, including skin improvement in patients with mycosis fungoides that express KIR3DL2 New pre-clinical data presented from next-generation NK cell engager platform, ANKET™, highlighted robust anti-tumor efficacy across several in vivo tumor models and manageable safety profile Cash position of €159.4 million1 as of June 30, 2021 Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. EDT Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for the six months ended June 30, 2021. The consolidated financial statements are attached to this press release. “In the first half of 2021, we had two key...

WAYNE, Pa. and ROCKVILLE, Md., Sept. 14, 2021 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (“Avalo” or the “Company”) (Nasdaq: AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases, announced today that it has entered into an underwriting agreement with Jefferies LLC and RBC Capital Markets, LLC under which the underwriters agreed to purchase, on a firm commitment basis, 12,500,000 shares of common stock of the Company, at a public offering price of $2.20 per share (the “Public Offering Price”). The offering is expected to close on or about September 17, 2021, subject to customary closing conditions. Jefferies and RBC Capital Markets are acting as joint...

KATY, Texas, Sept. 14, 2021 (GLOBE NEWSWIRE) — Academy Sports and Outdoors, Inc. (“Academy” or the “Company”) (NASDAQ: ASO) today announced the pricing of the previously announced underwritten secondary offering by certain of its stockholders that are affiliates of Kohlberg Kravis Roberts & Co. L.P. (the “Selling Stockholders”), of 18,645,602 shares of common stock of Academy at the public offering price of $44.75 per share, pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). No shares are being sold by Academy. The Selling Stockholders will receive all of the proceeds from this offering. Academy announced that, subject to the completion of the offering, it intends to repurchase 4,500,000 shares out of the 18,645,602 shares of common stock from the Selling...

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the pricing of its upsized initial public offering of 12,000,000 shares of its common stock at a public offering price of $17.00 per share. All of the shares are being offered by DICE. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by DICE, are expected to be $204.0 million. The shares are expected to begin trading on the Nasdaq Global Market on September 15, 2021 under the ticker symbol “DICE.” The offering is expected to close on...

MINNEAPOLIS, Sept. 14, 2021 (GLOBE NEWSWIRE) — Jamf Holding Corp. (“Jamf,” “we,” “us” or “our”) (NASDAQ: JAMF), the standard in Apple Enterprise Management, today announced the pricing of $325.0 million aggregate principal amount of Convertible Senior Notes due 2026 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Jamf also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on, and including, the first date on which the notes are issued, up to an additional $48.75 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on September 17, 2021, subject to customary...

CALGARY, Alberta, Sept. 14, 2021 (GLOBE NEWSWIRE) — Sugarbud Craft Growers Corp. (TSXV: SUGR, SUGR.DB, SUGR.WR, SUGR.WS, SUGR.WT) (OTCQB: SBUDF) (“Sugarbud” or the “Company“) is pleased to announce that its OTCQB listed common shares under the symbol SBUDF are now eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”) in the United States. “DTC eligibility supports our objectives to enhance liquidity while expanding our shareholder base and strengthening Sugarbud’s presence in the U.S. capital markets,” stated Sugarbud President and CEO, John Kondrosky. “With Sugarbud shares now traded electronically, existing shareholders benefit from greater liquidity and speed of trade execution, and new investors will be less restricted and have a much easier time participating...

REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) — PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (“PROCEPT”), a commercial-stage surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the pricing of its upsized initial public offering of 6,556,000 shares of its common stock at a public offering price of $25.00 per share, for total gross proceeds of $163.9 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by PROCEPT. PROCEPT’s common stock is expected to begin trading on the Nasdaq Global Market on September 15, 2021, under the ticker symbol “PRCT.” The offering is expected to close on September 17, 2021, subject to the satisfaction of customary closing...

MIAMI, FL, Sept. 14, 2021 (GLOBE NEWSWIRE) — EzFill Holdings, Inc. (“EzFill” or the “Company”), an emerging leader in the fast-growing on-demand mobile fuel industry, announced today the pricing of its initial public offering of 6,250,000 shares of its common stock at a public offering price of $4.00 per share, for gross proceeds of $25,000,000 before deducting underwriting discounts, commissions and offering expenses. In addition, EzFill has granted the underwriters a 45-day option to purchase up to an additional 937,500 shares of common stock solely to cover over-allotments. The shares of common stock are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “EZFL” on September 15, 2021. The offering is expected to close on September 17, 2021, subject to satisfaction of customary closing conditions. The...